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1.1. Peptidomimetic inhibitors of myeloid diﬀerentiation
factor 88
The nuclear transcription factor-jB (NF-jB) is known to
be involved in a host of physiological processes such as
inﬂammation, immunity and apoptosis. In response to
damaging stimuli, NF-jB activation is observed in most
cells involved in the immune response, such as neutrophils,
macrophages and lymphocytes. Thus, the immediate and
transitory activation of NF-jB is important to the normal
physiological response to pathogenic damage.
NF-jB recognises consensus sequences for the enhancers of
genes coding for pro-inﬂammatory cytokines (e.g., TNF,
IL-1, IL-2, IL-6 and IL-11), chemokines (e.g., IL-8, RAN-
TES and MIP-1R), adhesive molecules (ICAM-1, VCAM-
1, E-selectin), and enzymes producing inﬂammatory medi-
ators (iNOS and COX2). Dysregulation of this mechanism
through persistent and excessive activation, is associated
with chronic inﬂammatory diseases. The adaptor protein,
myeloid diﬀerentiation factor 88 (MyD88), is believed to
play a critical role in transduction events triggered by the
majority of TLR, IL-1 and IL-18 receptors, the result of
a postulated common transduction mechanism in the IL-
1R/TLR superfamily. Thus, inhibition of adaptor proteins
such as MyD88 which is involved in the activation of NF-
jB, is expected to be more eﬀective than inhibition of indi-
vidual ligand activities due to the mechanistic sharing of a
common transduction pathway.
The recent identiﬁcation of a critical sub-region of MyD88
Toll/IL-1 receptor (TIR) domain provides a starting point
for peptidomimetic ligand design and thus SAR explora-doi:10.1016/j.comche.2008.09.001
E-mail: nterrett@ensemblediscovery.comtion. Recent work has capitalised on this observation with
the intent to identify mimetics of this particular portion of
MyD88. Such mimetics could interfere with homodimerisa-
tion and thus prevent recruitment of MyD88 to each of the
IL-1R/TLR receptors and so interfer with their signalling.1
The approach taken in this recent work was to construct
mimetics of the consensus heptapeptide Ac-RDVLPGT-
NH2, belonging to the TIR domain of the adaptor protein
MyD88, by subdividing the region into three distinct
portions, consisting of a charged portion (Arg-Asp amino
acids), a hydrophobic portion (Val-Leu amino acids), and
a b-turn portion (Leu-Pro-Gly-Thr amino acids). When
combining all the available building blocks, a 4368 direct
and 234 retro-inverse peptidomimetic library was possible.
However, for practical reasons not all combinations were
synthesised, but rather a diverse set of 83 compounds
was prepared on solid-phase using (aminomethyl)polysty-
rene (Rink amide) resin.
Compounds chosen for synthesis all met the ‘Rule of Five’
and these underwent biological screening. The ability of the
peptidomimetics to inhibit protein–protein interactions
was assessed by a yeast 2-hybrid assay, and further
validated in a mammalian cell system by evaluating the
inhibition of NF-jB activation, a transcription factor
downstream of the MyD88 signalling pathway that allows
production of essential eﬀector molecules for immune and
inﬂammatory responses. The primary screening was ﬁrst
performed by using a 2-hybrid system (2HyS) in yeast Sac-
charomyces cerevisiae to evaluate the inhibition of MyD88
homodimerisation and then, a secondary functional test
was utilised to evaluate the inhibition of NF-jB in HeLa
cells.
From this library, several active compounds were obtained.
One of the most potent compounds tested was 1 which pos-
sessed inhibition (expressed as percentage inhibition at 100
lM) of 26% in the NF-jB assay.
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11.2. Acylguanidine inhibitors of b-secretase: optimisation of
substituents extending into the S1 and S3 substrate binding
pockets
Alzheimer’s disease, a progressive neurodegenerative dis-
ease, is the leading cause of dementia. Estimates vary be-
tween 5% to 50% that early onset Alzheimer’s disease
cases result from a variety of genetic mutations. The
remainder may therefore be classed as sporadic, with an
increasing risk of incidence with age. b-Amyloid plaques
are a recognisable feature of Alzheimer’s disease and are
formed by aggregation of amyloid ﬁbrils, which in turn
are formed from the neurotoxic amyloid b-peptide (Ab).
Proteolytic cleavage of amyloid precursor protein (APP) by
b-secretase (BACE-1) provides the membrane-bound b-C-
terminal fragment, which is itself cleaved by c-secretase
to generate Ab. BACE-1 inhibitors may therefore decrease
levels of Ab and have therapeutic beneﬁt in the treatment
of Alzheimer’s disease. A recent high throughput screening
campaign identiﬁed N-[2-(2,5-diphenyl-pyrrol-1-yl)-acetyl]-
guanidine (2) as an inhibitor of BACE-1 with low micro-
molar activity (IC50 = 3.7 lM, Kd = 2.8 lM), and this
compound also inhibited Ab formation in a cellular assay
with an IC50 of 8.9 lM. More recent work has undertaken
a hit-to-lead optimisation of this series of BACE-1
inhibitors.2N
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2The synthesis of target inhibitors proceeded via the synthe-
sis of 1,4-diarylbutane-1,4-diones (3), prepared in a one-
step cross-coupling reaction. The crude diketones were
coupled with glycine in an acid-catalysed condensation to
give (4), which were subsequently treated with a carbodiim-
ide-mediated coupling of the resultant pyrrole acetic acids
with guanidine hydrochloride to give the target acylguani-dines of general structure (5). A library of 156 singletons
was synthesised in this way, and all compounds produced
were assayed for BACE-1 inhibition in a ﬂuorescence reso-
nance energy transfer (FRET) assay at a concentration of
10 lM. One of the most potent compounds tested was
(6) which possessed an IC50 against BACE-1 of 0.6 lM.
Future studies on this series may focus on optimisation
of potency via improvements in interactions with the sub-
strate pocket.
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2. A summary of the papers in this month’s issue
2.1. Solid-phase synthesis
Eight tuftsin analogues, seven of which are novel, have
been synthesised on solid support. All the linear tuftsin
analogues contain an isopeptide bond, and modiﬁcation
of the tuftsin chain was based on the introduction of simple
amino acids such as valine, glycine, alanine and b-alanine
into the peptide chain at the e-amino group of lysine.3
Utilising polymer-bound anthranilic acid derivatives, 3,4-
dihydro-1H-2,1-benzothiazine-4-one 2,2-dioxide deriva-
tives were obtained through N-methanesulphonylation,
N-alkylation under Mitsunobu condition, and the cyclative
cleavage in 8–52% ﬁve-step overall isolated yields and 91–
99% purities from Wang resin.4
Using zinc triﬂate, the direct one-pot double cyclodehydra-
tion of linear tripeptides in the total synthesis of pyrazino-
[2,1-b]quinazoline-3,6-diones on solid support has been
achieved with good overall yields in short reaction times.
These syntheses of the pyrazino[2,1-b]quinazoline-3,6-
diones were conveniently achieved in only three steps,
starting from an amino acid-bound Wang resin.5
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cally and conformationally diverse macrocyclic peptidomi-
metics has been reported. A key feature of the method is
access to broad chemical and conformational diversity.6
2.2. Solution-phase synthesis
A convenient protocol for the parallel solution-phase syn-
thesis of a library of thiocarbamates, ureas, carbamates,
and amides from carbamoylimidazolium salts has been
developed. The crystalline carbamoylimidazolium salts
are readily synthesised from secondary amines, CDI and
iodomethane, and act as stable carbamoylation reagents.
A common set of reaction conditions and a straightforward
non-chromatographic liquid–liquid extraction puriﬁcation
protocol were developed for reactions with thiols, amines,
phenols, and carboxylic acids, giving the products in high
purities and yields.7
The synthesis of 1,4- and 1,5-disubstituted-1,2,3-triazolo-
nucleosides from various alkynes with 10-azido-20,30,50-tri-
O-acetylribose using either copper-catalysed azide-alkyne
cycloaddition (CuAAC) or ruthenium-catalysed azide-
alkyne cycloaddition (RuAAC), respectively have been
described. RuAAC and CuAAC are useful tools for the
synthesis of 1,2,3-triazolyl-nucleoside small libraries.8
2.3. Scaﬀolds and synthons for combinatorial libraries
Azido-protected Fmoc–Lys–OH was synthesised from
Fmoc–Lys–OH by the copper(II)-catalyzed diazo transfer
method, and introduced into a peptide by the ordinary
Fmoc-based solid-phase peptide synthesis. This azido pep-
tide could be condensed with a peptide thioester by the
Ag+-free thioester method without any signiﬁcant side
reactions, and the azido group was easily reduced to an
amino group by Zn powder after peptide condensation.9
A facile approach to the synthesis of acetonide and Fmoc-
protected 3,4-dihydroxyphenylalanine (DOPA), Fmoc-
DOPA(acetonide)-OH, has been reported. By protecting
the amino group of DOPA with a phthaloyl group and
the carboxyl group as a methyl ester, acetonide protection
of the catechol of DOPA derivative was realised in the
presence of p-toluenesulphonic acid. Following removal
of protecting groups, the intermediate was converted to
Fmoc-DOPA(acetonide)-OH, which was successfully
incorporated into a short DOPA-containing peptide, de-
rived from marine tubeworm cement proteins Pc1 and
Pc2.10
A straightforward synthesis of N-Fmoc-protected synthons
derived from a phosphinic analogue of methionine has
been reported. These precursors were used successfully
for the solid-phase synthesis of methionine-mimic phosph-
inopeptides using BOP-catalysed coupling without protec-
tion of the phosphoryl moiety.11
2.4. Solid-phase supported reagents
Polyisobutylene (PIB) is a useful soluble polymer support
that facilitates catalyst recovery and recycling in liquid–liquid biphasic systems because the long polyisobutylene
chain confers high phase selective solubility in the nonpolar
phase of polar–nonpolar liquid–liquid biphasic. Recent
work shows that PIB-supports that are eﬀective with metal
catalysts can also facilitate synthesis and use of organo-
catalysts. In particular, this is demonstrated by the use
of a PIB-supported pyridyl N-oxide to promote the allyla-
tion of several aromatic aldehydes with allyltrichloro-
silane.12
2.5. Novel resins, linkers and techniques
A new method for synthesising MBHA (4-methylbenzhydr-
ylamine) resin by benzotriazole-mediated amidoalkylation
has been reported. MBHA resin was eﬃciently prepared
with N-[(benzotriazol-1-yl)(p-tolyl)methyl]formamide or
N-[formamido(p-tolyl)methyl]formamide, and it showed
excellent properties as a solid support.13
A Pd(0) catalyst has been used to eﬀect allyl alkylation
reactions at pre-selected locations on an addressable micro-
electrode array. The reactions provide a new approach to
site-selective carbon–carbon bond formation and a new
method for placing substrates on the surface of a micro-
electrode array.14
2.6. Library applications
Bacteria of the genus Acinetobacter spp. are rapidly emerg-
ing as problematic pathogens in healthcare settings, exacer-
bated by the bacteria’s ability to form robust bioﬁlms. The
anti-bioﬁlm activity of a small library of second generation
oroidin analogues against the bacterium Acinetobacter
baumannii has been described.15
Fungal beauveriolide III, discovered as an inhibitor of lipid
droplet accumulation in mouse macrophages and showing
antiatherogenic activity in a mouse model, consists of
L-Phe, L-Ala, D-allo-Ile, and (3S,4S)-3-hydroxy-4-methyl-
octanoic acid moieties. A combinatorial library of beauve-
riolide analogues focusing on L-Ala and D-allo-Ile was
synthesised by combinatorial synthesis.16
Selective factor VIIa–tissue factor complex (FVIIa/TF)
inhibition is regarded as a promising target for developing
new anticoagulant drugs. Using parallel synthesis sup-
ported by structure-based drug design, peptidomimetic
FVIIa/TF inhibitors containing l-Gln or l-Met as the P2
moiety were identiﬁed. However, as these compounds
lacked the selectivity of other serine proteases in the coag-
ulation cascade, especially thrombin, further optimisation
was carried out with a focus on the P4 moiety.17
A series of piperidine carboxamides have been developed as
potent antagonists of the transient receptor potential vanil-
loid-1 (TRPV1), an emerging target for the treatment of
pain. A focused library of polar head groups led to the
identiﬁcation of a benzoxazinone amide that aﬀorded good
potency in cell-based assays.18
A solid phase synthesis method was established for the
synthesis of peptide-poly(ethylene glycol)-lipid (peptide-
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(OPD2000) was obtained and had conﬁrmed structure,
activity, and purity providing a targeting molecule for
preparation of well-deﬁned drug delivery systems, such as
targeted liposomes, for further studies.19
A library of ten novel benzenesulphonamides containing
triazole-tethered phenyl ‘tail’ moieties were synthesised by
a Cu(I) catalyzed 1,3-dipolar cycloaddition ‘click’ reaction
between 4-azido benzenesulphonamide and a panel of var-
iously substituted phenyl acetylenes. These compounds
were very eﬀective inhibitors (low nanomolar) of the
human mitochondrial carbonic anhydrase isozymes VA
and VB.20
The synthesis and antileishmanial activity of 18 edelfosine
analogues have been described. The compounds were ob-
tained in parallel combining solid phase and solution phase
synthesis. The most active analogue is characterised by the
octadecyl group in position 2 of the glycerol chain.21
NK2 antagonists have been reported to be potentially use-
ful for the treatment of a number of chronic diseases, such
as asthma, irritable bowel syndrome, cystitis, and depres-
sion. Starting from an in-house prepared library of capped
dipeptides, a series of molecules with subnanomolar bind-
ing aﬃnity for the hNK2 receptor have been identiﬁed.
These molecules are composed of three well-deﬁned
regions: a planar aromatic acyl system as N-terminal
capping group, a rigid and lipophilic core, and a ﬂexible
and relatively hydrophilic C-terminal capping group.22
A series of 53 rationally designed nitro derivatives have
been obtained by parallel synthesis and screened against
Leishmania donovani. Six compounds exhibited IC50
values lower than standard drugs, and brief SAR analysis
revealed that substitution is important to the activity.23
A library of functionalised 6-chloro-2-methoxy-(N9-substi-
tuted)acridin-9-amines structurally related to quinacrine
have been synthesised and evaluated for antiprion activity
on four diﬀerent cell models persistently infected with
scrapie prion strains (ScN2a, N167, Ch2) or a human
disease prion strain (F3). The most promising compound
was 6-chloro-2-methoxy-N-(4-(4-methylpiperazin-1-yl)-
phenyl)acridin-9-amine which had submicromolar EC50
values (0.1–0.7 lM) on all cell models, was able to clear
PrPSc at non-toxic concentrations of 1.2–2.5 lM, and was
more active than quinacrine in terms of EC50 values.
24
Human enterovirus (EV) belongs to the picornavirus fam-
ily, which consists of over 200 medically relevant viruses. A
peptidomimetic inhibitor AG7088 was developed to inhibit
the 3C protease of rhinovirus (a member of the family), a
chymotrypsin-like protease required for viral replication,
by forming a covalent bond with the active site Cys residue.
In this study, the recombinant 3C protease from EV71
(TW/2231/98), a particular strain which causes severe out-
breaks in Asia, has been prepared and inhibitors against
the protease and viral replication have been developed.
The study has provided potent inhibitors of the EV71 3C
protease as anti-EV71 agents and facilitates the combinato-rial synthesis of derivatives for further improving the inhib-
itory activity.25
A tetrahydroaminoquinoline-based library has been gener-
ated with the goal of ﬁnding small molecule modulators of
protein–protein interactions. Several library members as
well as other related intermediates were tested for their
ability to bind to Bcl-XL and Mcl-1 by in silico and
15N
NMR studies. An NMR study led to the identiﬁcation of
a tetrahydroaminoquinoline-based nude scaﬀold, as a weak
binder (Kd = 200 lM for Bcl-XL and Kd = 300 lM for
Mcl-1) to both proteins. Using this scaﬀold as the starting
material, a focused library of 9 derivatives was synthesised
by applying the principles of a fragment-based approach.26
An unusual class of diterpenoid natural products, ‘cyclo-
terpenals’ (with a central cyclohexadienal core), that arise
in nature by condensation of retinoids and other isoprenes,
have been isolated from a variety of organisms including
marine sponges as well as from the human eye. A synthetic
library of these molecules has been prepared and the ability
of this class of molecules to activate neurite outgrowth
activity reported.27
Solid-phase synthesis of a parallel library of 30-hydroxy-
2,3-dihydrobenzothiazepines has been carried out through
[4+3] annulation of a,b-unsaturated ketones with amino-
thiophenol, using Wang resin as solid support. The syn-
thesised compounds were evaluated for their potential
as antibacterial, tumour inhibitors as well as acetyl- and
butyrylcholinesterase inhibitors. Several compounds
showed signiﬁcant potential as crown gall tumour inhibi-
tors, reﬂecting a strong exploratory potential in search of
new benzothiazepines as source of anticancer agents.28
The design, synthesis and biological activity of a library of
substituted (biphenylcarbonyl)-tryptamine and (biphenyl-
carbonyl)-tetrahydro-b-carboline compounds related to
the natural product fascaplysin, as novel inhibitors of
CDK4/cyclin D1 has been reported. All of these molecules,
prepared using the Suzuki–Miyaura reaction, are selective
inhibitors of CDK4 over CDK2, with the most active
compounds having a CDK4 IC50 in the range 9–11 lM.29References
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